Dr. Joshua Hare To Present Longeveron Regenerative Stem Cell Research At The Sixth Annual Aspen BrainLab
July 13, 2018
Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that Dr. Joshua Hare, Chief Science Officer, will present at the sixth annual Aspen BrainLab on July 14. Aspen BrainLab brings together leading scientists and medical experts in neurology and is organized by the Aspen Brain Institute, which supports international brain research to fight brain disease.
NEWS PROVIDED BY
Jul. 13, 2018 14:53 ET
MIAMI, July 13, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that Dr. Joshua Hare, Chief Science Officer, will present at the sixth annual Aspen BrainLab on July 14. Aspen BrainLab brings together leading scientists and medical experts in neurology and is organized by the Aspen Brain Institute, which supports international brain research to fight brain disease.
In his presentation, “Can Stem Cells Spark the Regenerative Powers of the Human Brain?,” Dr. Hare will discuss the role Longeveron manufactured mesenchymal stem cells play to treat a host of human diseases related to brain health, cognition, and mood including Alzheimer’s disease and Aging Frailty.
“As the population ages and all of our lifespans increase, it has become critical to develop treatments that address aging to improve quality of life. A key concern shared by many is the loss of cognitive function with aging. Research and clinical trials strongly support a role for cell based therapy in enhancing brain health throughout life, and there are important groundbreaking clinical trials ongoing now,” Dr. Hare said.
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron’s MSCs are also approved for use in the Bahamas. As the only company to have a locally-approved allogeneic stem cell treatment, Longeveron currently is conducting a single-arm open label clinical trial for Aging Frailty in the Bahamas and is planning to add other indications to its Bahamas trial including cognitive disorders and orthopedic conditions.
Longeveron () is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
SOURCE Longeveron LLC